All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The GvHD Hub was pleased to speak with Robert Zeiser, Medical Center – University of Freiburg, Freiburg, DE, about the mechanisms of action of ibrutinib, ruxolitinib, and belumosudil, and their role in chronic graft-versus-host disease (cGvHD) treatment.
Mechanisms of action of ibrutinib, ruxolitinib, and belumosudil, and their role in cGvHD treatment
Zeiser begins by providing an overview of cGvHD and its implications for patients. This is followed by a discussion on three recently approved drugs, ibrutinib, ruxolitinib, and belumosudil, including their mechanisms of action in relation to cGvHD (Figure 1). Finally, Zeiser summarizes the clinical activity and recent trials investigating these drugs.
Figure 1. The mechanisms of action of ibrutinib, belumosudil, and ruxolitinib, and their treatment effects in cGvHD*
BCR, B-cell receptor; cGvHD, chronic graft-versus-host disease; ECM, extracellular matrix; IFN, interferon; IL, interleukin; TCR, T-cell receptor; Th17 cells, T helper 17 cells; T reg cells, regulatory T cells.
*Adapted from Zeiser et al.1
Editorial theme | Latest updates on cGvHD treatment
First-line treatment for chronic graft-versus-host disease (cGvHD), which consists of steroids, has not changed much over the last three decades. In the case of severe cGvHD, another...
ASH 2020 | Practice-changing abstracts in graft-versus-host disease
Did you miss ASH 2020? The GvHD Hub attended the 62nd ASH Annual Meeting & Exposition, December 5-8 2020, and has developed a downloadable resource on the practice-changing abstracts...
Subscribe to get the best content related to GvHD delivered to your inbox